TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2106162
Drug: Observation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation in the adjuvant treatment of high-grade sarcomas
Study: 6154838
Drug: Clonidine +
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine + Diuretic
Study: 6154838
Drug: Clonidine +
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine + Diuretic + Vasodilator
Study: 31162860
Drug: Humidified oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified oxygen therapy
Study: 31162860
Drug: Non-humidified oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-humidified oxygen therapy
Study: 7605521
Drug: Penicillinase-resistant antibiotics
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillinase-resistant antibiotics
Study: 2257957
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ranitidine plus placebo (group I)
Study: 2257957
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ranitidine plus 50 mg/day pirenzepine (group II)
Study: 2257957
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ranitidine plus 100 mg/day pirenzepine (group III)
Study: 2257957
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (analgesic activity)
Study: 29674981
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care with pain medication
Study: 29674981
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication (paracetamol, COX inhibitors, pregabalin)
Study: 28233311
Drug: UVA-1 phototherapy
Normalized name: UVA URSI
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVA-1 phototherapy at 30 J/cm2, escalated to 60 J/cm2 if hair regrowth was <75%, and further escalated to 120 J/cm2 if necessary; total of 25 sessions administered.
Study: 24547881
Drug: Isotretinoin 30
Normalized name: isotretinoin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 30 mg/day
Study: 21415430
Drug: Remifentanil-propofol combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil-propofol combinations (remifentanil 0.8 to 1.6 ng · mL(‐1) and propofol 1.5 to 2.7 μg · mL(‐1))
Study: 21415430
Drug: Remifentanil-propofol combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil-propofol combinations (remifentanil approximately 3.0 to 4.0 ng · mL(‐1) and propofol 0.0 to 1.1 μg · mL(‐1))
Study: 18362863
Drug: Sexual risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, younger age at sexual debut)
Study: 18362863
Drug: Sexual risk
Normalized name: Hep B, adolescent/high risk infant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual risk behaviors (e.g., > or =2 heterosexual partners in the past year, enrolling both sex and drug network members)
Study: 16608139
Drug: Liquid nutrition
Normalized name: Liquid Nutrition Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutrition supplement (200 ml) once daily immediately after diagnosis of infection
Study: 16608139
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (enriched food after referral to a dietician)
Study: 10450257
Drug: Nortriptyline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline at 80-120 ng/ml
Study: 10450257
Drug: Nortriptyline at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline at 40-60 ng/ml
Study: 7558388
Drug: Medical Grade
Normalized name: Skarcade Medical Grade Silicone Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Grade Silicone Rubber (MSR) with an oval 15 mm clamp, volume of 0.1531 +/- 0.0059 ml injected by five to six turns of the applicator handwheel.
Study: 486628
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (n = 22)
Study: 26670076
Drug: Unilateral dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral dose adjusted ovarian drilling (ULOD) using 60 Joules/cm(3) applied to the larger ovary
Study: 26670076
Drug: Bilateral ovarian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ovarian drilling (BLOD) with fixed doses of 1200 J
Study: 25141218
Drug: Laser+EX (diode
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser+EX (diode laser 980 nm, 20 W, fluence 37.5 J/cm², total energy 1200 J, thrice weekly for 3 weeks)
Study: 25141218
Drug: EX (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: EX (placebo laser therapy plus daily exercises)
Study: 22381711
Drug: Fimasartan 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 60/120 mg daily
Study: 22381711
Drug: Losartan 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50/100 mg daily
Study: 17224031
Drug: Test group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group: primary galvanic caps fabricated on implant abutments with a secondary cast noble alloy superstructure luted with resin cement (Nimetic Cem)
Study: 12518488
Drug: Oral‐B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B CrossAction (control manual toothbrush)
Study: 26286684
Drug: Positive focussing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive focussing on treatment information
Study: 26286684
Drug: Negative focussing
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative focussing on treatment information
Study: 26286684
Drug: Mixed aspects
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed aspects focussing on treatment information
Study: 15248886
Drug: Delayed-immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-immediate implant placement (Im)
Study: 15248886
Drug: Delayed single-tooth
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed single-tooth implant placement (De)
Study: 15248886
Drug: Overall implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implant treatment satisfaction (both groups)
Study: 15248886
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of implant surgery
Study: 11740133
Drug: Thyroxine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine therapy (mean dose 136 +/‐ 22 microg/day)
Study: 9237937
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg of ferrous gluconate (15 mg elemental iron) plus multivitamins
Study: 8479488
Drug: Dapsone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (50 mg per day) plus pyrimethamine (50 mg per week)
Study: 8479488
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (300 mg per month)
Study: 30789059
Drug: Befriending Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befriending Therapy (n=9)
Study: 30567595
Drug: Riociguat (1.0‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat (1.0‐2.5 mg tid)
Study: 25035080
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg) for 7 days
Study: 22884662
Drug: Two vaccinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vaccinations with Vero cell-derived whole virus non-adjuvanted H5N1 vaccine (7.5 μg HA Antigen A/Vietnam/1203/2004)
Study: 22884662
Drug: Booster vaccinations
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccinations at 6, 12-15, and 24 months with 7.5 μg A/Indonesia/05/2005
Study: 22884662
Drug: Booster vaccinations
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccinations with 3.75 μg A/Indonesia/05/2005
Study: 22884662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose priming with 7.5 μg A/Vietnam/1203/2004 followed by a 12 month booster (7.5 μg)
Study: 20418697
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery and again 3 months later.
Study: 20418697
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered before surgery.
Study: 20418697
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered after surgery.
Study: 20418697
Drug: Spanish version
Normalized name: Spanish thyme oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spanish version of the SF-8 health-related quality-of-life questionnaire administered to women.
Study: 18405411
Drug: Cisatracurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.1 mg kg‐1)
Study: 15747810
Drug: Mandible-protruding oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandible-protruding oral appliance
Study: 7861016
Drug: Stavudine 20
Normalized name: stavudine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 20 mg twice daily for patients > or = 60 kg
Study: 7861016
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg twice daily for patients > or = 60 kg
Study: 7861016
Drug: Stavudine 15
Normalized name: stavudine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 15 mg twice daily for patients weighing 40-59 kg
Study: 7861016
Drug: Stavudine 30
Normalized name: stavudine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 30 mg twice daily for patients weighing 40-59 kg
Study: 7861016
Drug: Stavudine 10
Normalized name: stavudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 10 mg twice daily for patients weighing < 40 kg
Study: 7861016
Drug: Stavudine 20
Normalized name: stavudine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 20 mg twice daily for patients weighing < 40 kg
Study: 27917567
Drug: 0.05% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% NaF solution
Study: 24548981
Drug: Mipomersen 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 50 mg SC
Study: 24548981
Drug: Mipomersen 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 100 mg SC
Study: 24548981
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg SC
Study: 23073811
Drug: Micro-implant group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-implant group
Study: 19526757
Drug: Chaiqin Chengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered immediately after hospitalization (early-treated group)
Study: 19526757
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical therapy (same for both groups)
Study: 19526757
Drug: Chaiqin Chengqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chaiqin Chengqi Decoction (CQCQD) administered 3 days after hospitalization (late-treated group)
Study: 17296341
Drug: Rimonabant 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 5 mg once daily
Study: 17296341
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg once daily
Study: 11681436
Drug: Quantitative culture
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantitative culture of the subcutaneous catheter segment using roll-plate and sonication methods
Study: 10216370
Drug: Antirejection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antirejection therapy for Group I (10 patients) for 7 days
Study: 10216370
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy for Group II (20 patients) for 2 weeks
Study: 7523479
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies to LH
Study: 28365225
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen at 0 and 3 months (group 1)
Study: 28365225
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose at 0 months (group 2)
Study: 28365225
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose at 0 months and a booster at 12 months (group 3)
Study: 25473078
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitor (PPI) for 8 weeks
Study: 18399039
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and cognitive therapy (CT)
Study: 18399039
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and interpersonal therapy (IPT)
Study: 15472659
Drug: Short-term nonsteroidal
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term nonsteroidal anti-inflammatory drugs and self-care instructions (palliative care group)
Study: 15472659
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs, self-care instructions, and occlusal appliance and mobilization therapy (physical medicine group)
Study: 2507061
Drug: Captopril (25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25‐100 mg/day for 12 months, average dose 40 mg daily during the second six months)
Study: 780037
Drug: Oxprenolol 20
Normalized name: oxprenolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Study: 780037
Drug: Propranolol 20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20 mg three times daily, increased to 40 and 80 mg if SDP exceeded 89 mm Hg
Study: 31278705
Drug: Intra-articular NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular NSAID Ketorolac injection
Study: 31278705
Drug: Intra-articular Hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular Hyaluronic acid injection
Study: 24832381
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment group (n=11)
Study: 24050956
Drug: Talactoferrin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talactoferrin (1.5 g p.o. BID)
Study: 19815148
Drug: Heavy orthodontic
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy orthodontic force of 225 g
Study: 19815148
Drug: Buccal surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal surface
Study: 15328177
Drug: Ep-CAM protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ep-CAM protein (400 microg/dose)
Study: 15328177
Drug: Anti-Id antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-Id antibody (500 microg/dose)
Study: 11210403
Drug: Oxycodone, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone, 5 mg p.o. Q4H and levofloxacin, 500 mg p.o. 1 hour after starting oxycodone
Study: 11210403
Drug: Levofloxacin, 500
Normalized name: LevoFLOXacin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, 500 mg p.o. alone
Study: 9468210
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (25 mg/min IA)
Study: 9468210
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (oral therapy for 4 weeks)
Study: 9468210
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (acute treatment)
Study: 9468210
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (chronic treatment)
Study: 28796130
Drug: Agonist-Antagonist (A-A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agonist-Antagonist (A-A) superset configuration
Study: 26722513
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (chemotherapy plus DC/CIK immunotherapy)
Study: 19073787
Drug: Rosiglitazone, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone, 3 mg/m²/d for 16 weeks
Study: 17042890
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) as an adjunct to pharmacological treatment
Study: 8588058
Drug: Trimipramine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine alone 200 mg/d (group 1)
Study: 8588058
Drug: Trimipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimipramine (200 mg/d) and additional serial partial sleep deprivation (3x/week) (group 2)
Study: 6165205
Drug: 0.025% budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% budesonide ointment
Study: 6165205
Drug: 0.025% fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% fluocinolone acetonide ointment
Study: 6165205
Drug: 0.010% budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.010% budesonide ointment
Study: 31747132
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors (empagliflozin and canagliflozin)
Study: 30111333
Drug: F@ce™ intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: F@ce™ intervention (8-week family-centred intervention with goal setting, problem-solving strategies, daily reminders, and self-rated follow-ups via SMS)
Study: 27394383
Drug: COPE intervention
Normalized name: Copernicia prunifera whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPE intervention (10 in-home occupational therapy visits, 1 in-home visit, and 1 telephone contact by an advanced practice nurse)
Study: 19484170
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly for 8 weeks
Study: 18787216
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg once daily)
Study: 18787216
Drug: Isoniazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (300 mg daily)
Study: 22417569
Drug: Heated and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated and humidified high-flow oxygen therapy (HHFO₂)
Study: 22417569
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (no humidification)
Study: 15800921
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement with isoflavones (soy+IF)
Study: 15800921
Drug: Soy supplement
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy supplement (both soy+IF and soy-IF)
Study: 10588212
Drug: High endotoxin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High endotoxin levels (beyond 50 pg/ml)
Study: 7047002
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus 'triple‐treatment' (vitamin D2 45000 iu twice weekly, sodium fluoride 50 mg and calcium phosphate 4.5 g daily)
Study: 31868983
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 2 L/min
Study: 31868983
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 4 L/min
Study: 31868983
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 6 L/min
Study: 31868983
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 8 L/min
Study: 29924955
Drug: Cisplatin plus
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin plus sodium thiosulfate (20 g/m² intravenously over 15 minutes, 6 hours after cisplatin)
Study: 29924955
Drug: Cisplatin alone
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin alone (80 mg/m² over 6 hours)
Study: 12243243
Drug: Hylan B
Normalized name: hylan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan B gel dressing
Study: 12243243
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no gel dressing)
Study: 8549224
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (SCH) 5,000 U every 12 hours
Study: 8549224
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of pneumatic compression stockings (PCS) and subcutaneous heparin (SCH)
Study: 1986565
Drug: Enalapril (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (angiotensin I converting enzyme inhibitor)
Study: 6134626
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal suspension (50 g charcoal)
Study: 31201785
Drug: Azithromycin treatment
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin treatment for 28 days
Study: 11338314
Drug: Untreated candidates
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated candidates for drug treatment
Study: 9544892
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids (budesonide or beclomethasone)